|
Related Companies
|
[]
|
||||||||
|
Related Funds
|
[]
|
||||||||
|
|
|||||||||
|
English
|
|||||||||
|
oda_MaterialEventDisclosureGeneralAbstract|
|
|
||||||||
|
oda_UpdateAnnouncementFlag|
|
|
Hayır (No)
|
|||||||
|
oda_CorrectionAnnouncementFlag|
|
|
Hayır (No)
|
|||||||
|
oda_DateOfThePreviousNotificationAboutTheSameSubject|
|
|
-
|
|||||||
|
oda_DelayedAnnouncementFlag|
|
|
Hayır (No)
|
|||||||
|
oda_AnnouncementContentSection|
|
|
||||||||
|
oda_ExplanationSection|
|
|
||||||||
|
oda_ExplanationTextBlock|
|
-Unofficial Translation- Towards the target of being global player of the pharmaceutical industry, GEN continue to its activities to develop activities abroad. In line with this goal, audit made by Germany Health Authority in GEN manufacturing facility and existing EU GMP (European Union Good Manufacturing Practices) certificate was updated for sterile production area. Accordingly, in addition to previous marketting authorization approvals marketting authorization approvals was made for new products in European Union (EU) countries. With the subjected certificate our Company's export potential to EU countries increased and positive impact on our Company's export activities is expected. |
||||||||